These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32445958)

  • 1. Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson's disease: Potential clinical and therapeutic implications.
    Angelopoulou E; Paudel YN; Shaikh MF; Piperi C
    Pharmacol Res; 2020 Aug; 158():104930. PubMed ID: 32445958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
    Shan S; Hong-Min T; Yi F; Jun-Peng G; Yue F; Yan-Hong T; Yun-Ke Y; Wen-Wei L; Xiang-Yu W; Jun M; Guo-Hua W; Ya-Ling H; Hua-Wei L; Ding-Fang C
    Neurobiol Aging; 2011 Mar; 32(3):443-58. PubMed ID: 19368990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease.
    Pabon MM; Bachstetter AD; Hudson CE; Gemma C; Bickford PC
    J Neuroinflammation; 2011 Jan; 8():9. PubMed ID: 21266082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of microgliosis, oxidative stress and associated neuroinflammation in the pathogenesis of Parkinson's disease: The therapeutic role of Nrf2 activators.
    Jayaram S; Krishnamurthy PT
    Neurochem Int; 2021 May; 145():105014. PubMed ID: 33689805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.
    Thome AD; Standaert DG; Harms AS
    PLoS One; 2015; 10(10):e0140566. PubMed ID: 26469270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death.
    Suzuki M; El-Hage N; Zou S; Hahn YK; Sorrell ME; Sturgill JL; Conrad DH; Knapp PE; Hauser KF
    Mol Neurodegener; 2011 Nov; 6():78. PubMed ID: 22093090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
    Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
    Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications.
    Wilms H; Zecca L; Rosenstiel P; Sievers J; Deuschl G; Lucius R
    Curr Pharm Des; 2007; 13(18):1925-8. PubMed ID: 17584117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders.
    Pawelec P; Ziemka-Nalecz M; Sypecka J; Zalewska T
    Cells; 2020 Oct; 9(10):. PubMed ID: 33065974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.
    Subbarayan MS; Joly-Amado A; Bickford PC; Nash KR
    Pharmacol Ther; 2022 Mar; 231():107989. PubMed ID: 34492237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease.
    Morganti JM; Nash KR; Grimmig BA; Ranjit S; Small B; Bickford PC; Gemma C
    J Neurosci; 2012 Oct; 32(42):14592-601. PubMed ID: 23077045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 modulates microglial activity through regulation of chemokine (C-X3-C) receptor 1 -mediated signalling pathways.
    Ma B; Xu L; Pan X; Sun L; Ding J; Xie C; Koliatsos VE; Cai H
    Hum Mol Genet; 2016 Aug; 25(16):3515-3523. PubMed ID: 27378696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractalkine/CX3CR1 is involved in the cross-talk between neuron and glia in neurological diseases.
    Luo P; Chu SF; Zhang Z; Xia CY; Chen NH
    Brain Res Bull; 2019 Mar; 146():12-21. PubMed ID: 30496784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subthalamic nucleus deep brain stimulation suppresses neuroinflammation by Fractalkine pathway in Parkinson's disease rat model.
    Chen Y; Zhu G; Liu D; Zhang X; Liu Y; Yuan T; Du T; Zhang J
    Brain Behav Immun; 2020 Nov; 90():16-25. PubMed ID: 32726685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes.
    Mecca C; Giambanco I; Donato R; Arcuri C
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
    Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokine CX3CL1 (Fractalkine) Signaling and Diabetic Encephalopathy.
    Wątroba M; Grabowska AD; Szukiewicz D
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.